Core Viewpoint - Changjiang Life Sciences Technology (00775) has established a Scientific Advisory Committee to enhance its research capabilities and navigate the complexities of global drug development [1] Group 1: Company Developments - The stock of Changjiang Life Sciences Technology has seen an increase of over 4%, currently trading at 0.87 HKD with a transaction volume of 31.7098 million HKD [1] - The newly formed Scientific Advisory Committee consists of independent experts from academia, clinical research, and the industry, including notable figures such as former Secretary for Food and Health Ko Wing-man and clinical professor at HKU, Dr. Hsu Yi-wen [1] Group 2: Strategic Initiatives - The committee is a strategic organization aimed at providing scientific, clinical, and regulatory guidance to support the company's research projects, particularly in the development of therapeutic cancer vaccines [1] - The Scientific Advisory Committee will offer professional resources to help the company address the increasingly complex global drug development environment, mitigate risks, and expedite regulatory approvals and patient access [1]
长江生命科技现涨超4% 公司成立科学顾问委员会 推进科研项目全速前进